{
  "hypothesis": "h204",
  "title": "Lymphoma Subtype Stratification",
  "status": "validated",
  "finding": "Lymphoma and leukemia have EQUAL drug overlap; improvement requires mechanism-based rules",
  "key_results": {
    "drug_overlap_comparison": {
      "lymphoma_mean_jaccard": "6.0%",
      "leukemia_mean_jaccard": "5.9%",
      "ratio": "1.0x (identical)",
      "conclusion": "Lymphoma does NOT share more drugs across subtypes than leukemia"
    },
    "pan_drug_analysis": {
      "lymphoma_pan_drugs": 21,
      "leukemia_pan_drugs": 23,
      "lymphoma_disease_coverage": "83% (29/35)",
      "leukemia_disease_coverage": "78% (38/49)",
      "conclusion": "Similar pan-drug patterns"
    },
    "mechanism_based_groupings": {
      "CD30_positive": {
        "drug": "Adcetris (brentuximab vedotin)",
        "diseases": 9,
        "types": [
          "Hodgkin",
          "ALCL",
          "PTCL",
          "CTCL"
        ]
      },
      "CD20_positive": {
        "drug": "Rituximab",
        "diseases": 6,
        "types": [
          "B-cell NHL",
          "DLBCL",
          "FL",
          "Burkitt"
        ]
      }
    }
  },
  "actionable_insight": "Lymphoma can be improved via mechanism-based rules (CD30+, CD20+) rather than general subtype overlap",
  "recommended_rules": [
    {
      "rule": "CD30+ lymphoma + Adcetris/brentuximab",
      "keywords": [
        "hodgkin",
        "anaplastic large cell",
        "ALCL",
        "T-cell lymphoma"
      ],
      "tier": "HIGH"
    },
    {
      "rule": "CD20+ lymphoma + rituximab",
      "keywords": [
        "B-cell",
        "follicular",
        "DLBCL",
        "burkitt",
        "NHL"
      ],
      "tier": "HIGH"
    }
  ]
}